Andrew John Partridge
Net Worth
Last updated:
What is Andrew John Partridge net worth?
The estimated net worth of Mr. Andrew John Partridge is at least $5,602,331 as of 9 Feb 2022. He owns shares worth $1,678,149 as insider, has earned $8,022 from insider trading and has received compensation worth at least $3,916,160 in Turning Point Therapeutics, Inc..
What is the salary of Andrew John Partridge?
Mr. Andrew John Partridge salary is $979,040 per year as Executive Vice President & Chief Commercial Officer in Turning Point Therapeutics, Inc..
How old is Andrew John Partridge?
Mr. Andrew John Partridge is 56 years old, born in 1969.
What stocks does Andrew John Partridge currently own?
As insider, Mr. Andrew John Partridge owns shares in one company:
| Company | Title | Shares | Price per share | Total value |
|---|---|---|---|---|
| Turning Point Therapeutics, Inc. (TPTX) | Executive Vice President & Chief Commercial Officer | 22,078 | $76.01 | $1,678,149 |
What does Turning Point Therapeutics, Inc. do?
Turning Point Therapeutics, Inc., a clinical-stage precision oncology biopharmaceutical company, engages in designing and developing therapies that target genetic drivers of cancer. It develops a pipeline of tyrosine kinase inhibitors (TKIs) that targets genetic drivers of cancer in TKI-naïve and TKI-pretreated patients. The company's lead drug candidate repotrectinib is being evaluated in an ongoing Phase 1/2 trial called TRIDENT-1 for the treatment of patients with ROS1+ advanced non-small-cell lung cancer (NSCLC) and patients with ROS1+ and NTRK+ advanced solid tumors. It also develops TPX-0022, a MET/SRC/CSF1R inhibitor, which is in Phase 1 SHIELD-1 clinical trial for patients with advanced solid tumors harboring genetic alterations in MET; TPX-0046, a RET inhibitor that is in 1/2 SWORD-1 clinical trial for patients with advanced solid tumors harboring RET genetic alterations; and TPX-0131, an ALK inhibitor, which is in Phase 1/2 FORGE-1 study for patient with advanced or metastatic TKI-pretreated ALK-positive NSCLC. Turning Point Therapeutics, Inc. was founded in 2013 and is headquartered in San Diego, California. As of August 15, 2022, Turning Point Therapeutics, Inc. operates as a subsidiary of Bristol-Myers Squibb Company.
Andrew John Partridge insider trading
Turning Point Therapeutics, Inc.
Mr. Andrew John Partridge has made 2 insider trades between 2021-2022, according to the Form 4 filled with the SEC. Most recently he sold 221 units of TPTX stock worth $8,022 on 9 Feb 2022.
The largest trade he's ever made was exercising 1,869 units of TPTX stock on 14 Jul 2021. As of 9 Feb 2022 he still owns at least 22,078 units of TPTX stock.
Turning Point Therapeutics key executives
Turning Point Therapeutics, Inc. executives and other stock owners filed with the SEC:
- Dr. Athena Maria Countouriotis M.D. (53) Pres, Chief Executive Officer & Director
- Dr. Siegfried Reich Ph.D. (65) Executive Vice President & Chief Scientific Officer
- Mr. Andrew John Partridge (56) Executive Vice President & Chief Commercial Officer
- Ms. Annette C. North Esq., LLB (59) Executive Vice President, Gen. Counsel & Company Sec.